Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Previously, we performed an RCT in patients with various immune-disorders and observed that supplementation with 4000 IU vitamin D/day during 12 months significantly reduced antibiotic consumption and RTIs.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Observational study.

Observational study

Observes exposures and outcomes without assigning the exposure; the subtype is not established here.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Vitamin D3 Supplementation and Antibiotic Consumption: Results from a Prospective, Observational Study at an Immune-Deficiency Unit in Sweden

Source: Article title.

Patients were recruited from the Immunodeficiency Unit, Infectious Disease Clinic, Karolinska University Hospital, Stockholm, Sweden, between March 2013 to October 2013.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Vitamin D3 Supplementation and Antibiotic Consumption: Results from a Prospective, Observational Study at an Immune-Deficiency Unit in Sweden

Observational study · PLoS ONE · 2016

Original publication title

Vitamin D3 Supplementation and Antibiotic Consumption: Results from a Prospective, Observational Study at an Immune-Deficiency Unit in Sweden

Anna-Carin Norlin; Susanne Hansen; Emilie Wahren-Borgström; Carl Granert; Linda Björkhem-Bergman; Peter Bergman

© 2016 Norlin et al

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Vitamin D3 supplementation of 1600 IE /day is safe to use in immunodeficient patients with 25-OHD levels less than 75 nmol/L and significantly reduced the antibiotic consumption in patients without immunoglobulin substitution.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

Vitamin D supplementation has been proposed to improve clinical symptoms during respiratory tract infections (RTIs), but results from randomized, placebo-controlled trials (RCT) are inconclusive. Previously, we performed an RCT in patients with various immune-disorders and observed that supplementation with 4000 IU vitamin D/day during 12 months significantly reduced antibiotic consumption and RTIs. This formed the basis for new guidelines at our unit; i.e. patients with insufficient levels of 25-hydroxyvitamin D (≤75 nmol/L) are now offered vitamin D supplementation. The aim of this prospective follow-up study was to evaluate the outcome of these new recommendations with regard to antibiotic consumption in our unit.

Source: Background

Abstract: What methods does the paper describe?

277 patients with insufficiency were supplemented with vitamin D3, 1500 to 1600 IU/day for 12 months. Each patient was its own control and data on antibiotic consumption was monitored 12 months before and 12 months after initiation of vitamin D3 supplementation.

Source: Method

Abstract: Results

Vitamin D3 supplementation resulted in a significantly reduced antibiotic consumption, from 20 to 15 days/patient (p<0.05). The number of antibiotic-free patients increased from 52 to 81 after vitamin D3 supplementation; OR 1.79; 95% CI 1.20 to 2.66 (p<0.01). The number of antibiotic-prescriptions decreased significantly, a finding that mainly was attributed to a reduction of respiratory tract antibiotics (p<0.05). Subgroup analysis showed that only patients without immunoglobulin substitution (n = 135) had a significant effect of vitamin D supplementation.

Source: Results

Abstract: Conclusion

Vitamin D3 supplementation of 1600 IE /day is safe to use in immunodeficient patients with 25-OHD levels less than 75 nmol/L and significantly reduced the antibiotic consumption in patients without immunoglobulin substitution.

Source: Conclusion
Authors’ abstract

Background

Vitamin D supplementation has been proposed to improve clinical symptoms during respiratory tract infections (RTIs), but results from randomized, placebo-controlled trials (RCT) are inconclusive. Previously, we performed an RCT in patients with various immune-disorders and observed that supplementation with 4000 IU vitamin D/day during 12 months significantly reduced antibiotic consumption and RTIs. This formed the basis for new guidelines at our unit; i.e. patients with insufficient levels of 25-hydroxyvitamin D (≤75 nmol/L) are now offered vitamin D supplementation. The aim of this prospective follow-up study was to evaluate the outcome of these new recommendations with regard to antibiotic consumption in our unit.

Method

277 patients with insufficiency were supplemented with vitamin D3, 1500 to 1600 IU/day for 12 months. Each patient was its own control and data on antibiotic consumption was monitored 12 months before and 12 months after initiation of vitamin D3 supplementation.

Results

Vitamin D3 supplementation resulted in a significantly reduced antibiotic consumption, from 20 to 15 days/patient (p<0.05). The number of antibiotic-free patients increased from 52 to 81 after vitamin D3 supplementation; OR 1.79; 95% CI 1.20 to 2.66 (p<0.01). The number of antibiotic-prescriptions decreased significantly, a finding that mainly was attributed to a reduction of respiratory tract antibiotics (p<0.05). Subgroup analysis showed that only patients without immunoglobulin substitution (n = 135) had a significant effect of vitamin D supplementation.

Conclusion

Vitamin D3 supplementation of 1600 IE /day is safe to use in immunodeficient patients with 25-OHD levels less than 75 nmol/L and significantly reduced the antibiotic consumption in patients without immunoglobulin substitution.

Publication and source details

Original title: Vitamin D3 Supplementation and Antibiotic Consumption: Results from a Prospective, Observational Study at an Immune-Deficiency Unit in Sweden

Anna-Carin Norlin; Susanne Hansen; Emilie Wahren-Borgström; Carl Granert; Linda Björkhem-Bergman; Peter Bergman

PLoS ONE · 2016

Competing Interests: The authors have declared that no competing interests exist.

  • Conceptualization: ACN SH PB.

  • Data curation: ACN SH.

  • Formal analysis: LBB PB.

  • Funding acquisition: LBB PB.

  • Investigation: ACN SH EW CG PB.

  • Methodology: ACN SH PB.

  • Project administration: PB.

  • Resources: ACN SH EW CG PB.

  • Supervision: LBB PB.

  • Validation: ACN SH LBB PB.

  • Visualization: LBB.

  • Writing: original draft: LBB PB.

  • Writing: review & editing: ACN SH EW CG LBB PB.

‡ These authors share last authorship on this work.

* E-mail: peter.bergman@ki.se
© 2016 Norlin et al2016Norlin et alhttps://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.http://dx.doi.org/10.13039/501100002794CancerfondenBjörkhem-Bergman Linda http://dx.doi.org/10.13039/501100004359VetenskapsrådetBergman Peter http://dx.doi.org/10.13039/501100003793Hjärt-LungfondenBergman Peter http://dx.doi.org/10.13039/501100006285Magnus Bergvalls StiftelseBergman Peter http://dx.doi.org/10.13039/501100006285Magnus Bergvalls StiftelseBjörkhem-Bergman Linda Financial support was provided through the regional agreement on training and clinical research (ALF) between Karolinska Institutet and Stockholm County Council (PB and LBB), Swedish Foundation for Cancer Research (LBB), Magnus Bergwall Foundation (PB and LBB), Karolinska Institutet (PB and LBB) and the Swedish Research Council (PB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-12T09:05:01.001637+00:00

DOI: 10.1371/journal.pone.0163451 · PMC5033385